PATH [to 6 May 2017]
Press release | May 01, 2017
Biovac and PATH announce partnership to develop novel vaccine against newborn infection
South African manufacturer will be the first in a low-resource country to develop a vaccine against Group B Streptococcus vaccine, a leading cause of severe infection in infants
Durban, South Africa, 2 May 2017—The South Africa–based Biovac Institute (Biovac) and PATH, an international health organization, are pleased to announce the launch of a collaborative partnership to develop a novel vaccine against Group B Streptococcus (GBS), supported by a grant from the Bill & Melinda Gates Foundation. The partnership was announced today at the Innovation Effect Africa symposium held alongside the World Economic Forum event in Durban.
Biovac, a public-private partnership based in Cape Town, will be one of only three companies in the world and the only developing-country vaccine manufacturer to develop a novel conjugate vaccine against GBS….
Announcement | May 01, 2017
PATH Statement on the US Fiscal Year 2017 Appropriations Bill
PATH Applauds Congress for Protecting Vital Health Programs
Press release | May 01, 2017
Powering African innovation for health and economic growth
Leaders convene ahead of the World Economic Forum on Africa to accelerate investment in African-led innovation
Human Vaccines Project [to 6 May 2017]
03 May, 2017
Jose-Maria Fernandez Joins The Human Vaccines Project Board Of Directors
NEW YORK, May 3, 2017 /PRNewswire-USNewswire/ — The Human Vaccines Project, a nonprofit public-private partnership focused on decoding the immune system to improve human health, today announced the board appointment of Jose-Maria Fernandez, managing partner at Altamar Credit, Altamar Capital Partners LLC. Fernandez brings extensive experience in economics, finance and capital markets to the post. He formerly served as Director General of the Spanish Treasury.
“Jose-Maria brings deep expertise in financial markets in the US and Europe. Engaging him as part of our team will strengthen our current board as we continue to expand our project and reach,” said Wayne C. Koff, president and CEO of the Human Vaccines Project. “Along with his background in business leadership and finance, he brings a strong personal commitment to seeing biomedical research expand and improve to advance global public health.”…
Global Fund [to 6 May 2017]
Global Fund Accelerates Efforts To End Epidemics
04 May 2017
KIGALI, Rwanda – At its 37th Meeting, the Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria took significant steps toward increasing impact and maximizing effectiveness in its goal of ending epidemics, which will achieve greater health security and long-term prosperity.
Taking on serious challenges like expanding impact in public health as more countries transition toward domestic funding, the Board addressed numerous issues on how to continue to expand prevention, treatment and care for people affected by HIV, TB and malaria in the coming years.
The Global Fund is embedding into its work the principles and practices of a new policy on sustainability, transition and co-financing. It aims to leverage additional sources of funding, strengthen domestic investment and co-financing of core interventions, while planning for long-term transition.
In his final address to the Board, outgoing Executive Director Mark Dybul weaved together global dynamics as he pointed to a clear direction for the Global Fund: working together collaboratively, optimizing portfolio management, improving program quality and efficiency, and constantly looking for ways to maximize the impact of funds in countries where we invest. Dr. Dybul completes a four-year term on 31 May 2017. Marijke Wijnroks, currently Chief of Staff, will serve as Interim Executive Director until the Board selects a replacement for Dr. Dybul.
The Board confirmed an Executive Director Nomination Committee with nine members to oversee the search for the Global Fund’s next Executive Director. The Global Fund anticipates soliciting applications for the position beginning in early June, and intends to select a new Executive Director at the Board’s next meeting in November 2017…
Global Fund Board Selects New Chair and Vice-Chair
03 May 2017
KIGALI, Rwanda – The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria selected Aida Kurtović as its new Chair, after serving as Vice-Chair for the past two years. The Board also selected Ambassador John Simon as incoming Vice-Chair.
Kurtović, who is from Bosnia and Herzegovina, was selected for a two-year term during a Board meeting that is being hosted by the government of Rwanda…
As Chair of the Board, Kurtović succeeds Norbert Hauser of Germany, whose term began in April 2015.
Ambassador John Simon, selected as Vice-Chair of the Board, is a distinguished government official with special expertise in innovative finance, and is currently founder and managing partner of Total Impact Capital, an impact investing firm. He has served as United States Ambassador to the African Union, and as Executive Vice President of the Overseas Private Investment Corporation (OPIC)…
UNAIDS [to 6 May 2017]
Selected Press Releases & Updates
PEPFAR is on track to deliver yet more results
04 May 2017
Since its establishment in 2003, the United States President’s Emergency Plan for AIDS Relief (PEPFAR) has saved millions of lives. In 2016, around 11.5 million people living with HIV had access to antiretroviral treatment through PEPFAR-funded programmes, including 1.1 million children. Nearly 2 million babies born to women living with HIV were born HIV-free, and 6.2 million orphans and other vulnerable children received care and support.
In addition, PEPFAR funding supported more than 11.7 million voluntary medical male circumcision procedures to help prevent HIV acquisition and one million adolescent girls and young women were reached through the DREAMS initiative in 10 countries in sub-Saharan Africa.
And PEPFAR is on track to continue to deliver yet more results. Through a series of consultations over the past three months, PEPFAR has completed planning for its 2017 funding cycle to support more than 30 countries through Country Operational Plans…
Generating evidence to ensure HIV is part of social protection
04 May 2017
Widely used in developed countries to maintain living standards and address transient poverty, social protection has now become an essential element of modern development efforts. Social protection in developing countries encompasses a range of programmes designed to help lift people out of poverty and prevent, manage and overcome situations that adversely affect their well-being.
To ensure that HIV is considered and integrated appropriately into social protection programmes, UNAIDS and partners have developed an HIV and social protection assessment tool. The tool has been designed to analyse social protection schemes and establish whether they take into account the needs of people at higher risk of contracting HIV and people living with and affected by the virus…
IVI [to 6 May 2017]
IVI Annual Report 2015
[Excerpt from introductory letter from IVI Director General Jerome H. Kim, MD]
…IVI is the first international organization hosted by the Republic of Korea, which has since seen the establishment of several international organizations and UN offices. We are pleased to South Korea’s partner in international cooperation efforts, particularly in global health. We also appreciate the long-standing support and trust of our other key funders, Sweden and the Bill & Melinda Gates Foundation.
Shortly after my appointment, it was universally agreed that IVI was in need of revitalization so we underwent a strategic refresh in 2015. With support from the Boston Consulting Group (BCG), we reviewed and reevaluated our core capabilities and redefined our direction. The eight-month long process resulted in major organizational and strategic changes for the organization:
:: Revised mission statement to reflect our expanded focus on new and emerging diseases of global health importance such as MERS.
:: Articulation of a more clear direction that builds on our best-in-class product development and translational capabilities.
:: Renewed focus on diseases where we have exceptional expertise and experience, such as cholera, typhoid, dengue, hepatitis E, and MERS.
:: Reorganized scientific structure designed to facilitate cross-departmental communication and to focus talent against highest priority activities.
:: Streamlined core cost structure that ensures financial sustainability and operational efficiency.
:: Renewed focus on strengthening relationships with key funders and stakeholders to ensure IVI will be at the forefront of efforts to develop affordable vaccines for global health…
Wellcome Trust [to 6 May 2017]
Opinion / Published: 3 May 2017
Is public mistrust of expertise damaging research?
What does the world think about ‘experts’ – and how does that make you feel? We’re exploring the role of expertise in research, policy making and wider society in our four-week #ExpertDebate.
Over the past couple of years, there seems to have been a pushback in society on ‘experts’, whether it’s politicians saying that people have had enough of experts, or a rejection of scientific consensus on issues such as climate change, vaccination, or evidence-based decision-making.
We think this could be hindering the environment for research to thrive. So we’re holding a four-week debate on Facebook (opens in a new tab) and Twitter (opens in a new tab) to explore the role of expertise, find out what the issues are and see what, if anything, Wellcome as an organisation might be able to do to help…
European Medicines Agency [to 6 May 2017]
New guide on biosimilar medicines for healthcare professionals
Increasing understanding of biosimilar medicines
The European Medicines Agency (EMA) and the European Commission have published an information guide for healthcare professionals on biosimilar medicines. Biosimilars are biological medicines that are highly similar in all essential aspects to a biological medicine that has already been authorised.
The objective of the guide is to provide healthcare professionals with reference information on both the science and regulation underpinning the use of biosimilars.
“Today, biosimilars are an integral part of the effective biological therapies available in the EU,” said Professor Guido Rasi, EMA’s Executive Director. “Given the role of healthcare professionals on the front line of patient care, it is vital that they have access to reliable information on these medicines: what they are and how they are developed, approved and monitored.”…